CL2011002020A1 - Metodo in vitro para modificar el perfil de celulas treg presentes en una poblacion total de esplenocitos de una muestra biologica porque comprende aislar, cultivar y exponer los esplenocitos a un medio de atp y polimixina b.10 ug/ml a 100 ug/ml y uso combinado de polomixina b y atp para preparar un medicamento util en el tratamiento de tumores. - Google Patents

Metodo in vitro para modificar el perfil de celulas treg presentes en una poblacion total de esplenocitos de una muestra biologica porque comprende aislar, cultivar y exponer los esplenocitos a un medio de atp y polimixina b.10 ug/ml a 100 ug/ml y uso combinado de polomixina b y atp para preparar un medicamento util en el tratamiento de tumores.

Info

Publication number
CL2011002020A1
CL2011002020A1 CL2011002020A CL2011002020A CL2011002020A1 CL 2011002020 A1 CL2011002020 A1 CL 2011002020A1 CL 2011002020 A CL2011002020 A CL 2011002020A CL 2011002020 A CL2011002020 A CL 2011002020A CL 2011002020 A1 CL2011002020 A1 CL 2011002020A1
Authority
CL
Chile
Prior art keywords
polymyxin
splenocytes
atp
tumors
culturing
Prior art date
Application number
CL2011002020A
Other languages
English (en)
Inventor
Acuna Claudio
Capelli Claudio
Escobar Alejandro
Coddou Claudio
Imarai Monica
Labra Yohana
Lopez Ximena
Rios Miguel
Original Assignee
Univ Santiago Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Santiago Chile filed Critical Univ Santiago Chile
Priority to CL2011002020A priority Critical patent/CL2011002020A1/es
Publication of CL2011002020A1 publication Critical patent/CL2011002020A1/es
Priority to PCT/CL2012/000043 priority patent/WO2013023319A1/es
Priority to US14/181,810 priority patent/US20140371159A1/en
Priority to US15/013,320 priority patent/US20160287661A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método in vitro para modificar el perfil de células treg presentes en una población total de esplenocitos de una muestra biológica porque comprende aislar, cultivar y exponer los esplenocitos a un medio de atp y polimixina b.10 ug/ml a 100 ug/ml y uso combinado de polomixina b y atp para preparar un medicamento útil en el tratamiento de tumores.
CL2011002020A 2011-08-18 2011-08-18 Metodo in vitro para modificar el perfil de celulas treg presentes en una poblacion total de esplenocitos de una muestra biologica porque comprende aislar, cultivar y exponer los esplenocitos a un medio de atp y polimixina b.10 ug/ml a 100 ug/ml y uso combinado de polomixina b y atp para preparar un medicamento util en el tratamiento de tumores. CL2011002020A1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CL2011002020A CL2011002020A1 (es) 2011-08-18 2011-08-18 Metodo in vitro para modificar el perfil de celulas treg presentes en una poblacion total de esplenocitos de una muestra biologica porque comprende aislar, cultivar y exponer los esplenocitos a un medio de atp y polimixina b.10 ug/ml a 100 ug/ml y uso combinado de polomixina b y atp para preparar un medicamento util en el tratamiento de tumores.
PCT/CL2012/000043 WO2013023319A1 (es) 2011-08-18 2012-08-17 Método in vitro para modificar el perfil de depleción de células treg presentes en una población total de esplenocitos de una muestra biológica al aislar, cultivar y exponer los mismos a un medio de atp y polimixina b
US14/181,810 US20140371159A1 (en) 2011-08-18 2014-02-17 In vitro method for modifying the depletion profile of treg cells present in a total splenocyte population of a biological sample by means of the isolation, culturing and exposure thereof to an atp and polymixin b medium
US15/013,320 US20160287661A1 (en) 2011-08-18 2016-02-02 Method for treating cancer by administering atp and polymyxin b

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2011002020A CL2011002020A1 (es) 2011-08-18 2011-08-18 Metodo in vitro para modificar el perfil de celulas treg presentes en una poblacion total de esplenocitos de una muestra biologica porque comprende aislar, cultivar y exponer los esplenocitos a un medio de atp y polimixina b.10 ug/ml a 100 ug/ml y uso combinado de polomixina b y atp para preparar un medicamento util en el tratamiento de tumores.

Publications (1)

Publication Number Publication Date
CL2011002020A1 true CL2011002020A1 (es) 2012-04-20

Family

ID=50279004

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002020A CL2011002020A1 (es) 2011-08-18 2011-08-18 Metodo in vitro para modificar el perfil de celulas treg presentes en una poblacion total de esplenocitos de una muestra biologica porque comprende aislar, cultivar y exponer los esplenocitos a un medio de atp y polimixina b.10 ug/ml a 100 ug/ml y uso combinado de polomixina b y atp para preparar un medicamento util en el tratamiento de tumores.

Country Status (3)

Country Link
US (2) US20140371159A1 (es)
CL (1) CL2011002020A1 (es)
WO (1) WO2013023319A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049372A (en) * 1982-07-13 1991-09-17 Eliezer Rapaport Anticancer activities in a host by increasing blood and plasma adenosine 5'-triphosphate (ATP) levels
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CN1313104C (zh) 2005-05-27 2007-05-02 中国科学院南海海洋研究所 一种具有柴胡和多霉素协同作用的抗癌药物组合物

Also Published As

Publication number Publication date
US20140371159A1 (en) 2014-12-18
WO2013023319A1 (es) 2013-02-21
US20160287661A1 (en) 2016-10-06
WO2013023319A8 (es) 2014-03-20

Similar Documents

Publication Publication Date Title
CL2020002805A1 (es) Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)
EP4324913A3 (en) Culture media for stem cells
MX2019012311A (es) Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso.
AU2012274478A8 (en) Method for amplifying NK cells
MY197851A (en) Antibody formulations
MX2014005710A (es) Un metodo de cribado de farmaco y usos del mismo.
MX2012000897A (es) Diferenciacion de celulas madre embrionarias humanas.
MX2016008251A (es) Medios para cultivo celular.
MX2016013963A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
MY171710A (en) Culture medium composition, and method for culturing cell or tissue using said composition
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
MX2016006620A (es) Receptores de células t humanas con alta afinidad modificados por medio de manipulación genetica.
UY33899A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
MX2015014892A (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
MX376437B (es) Uso de hígado descelularizado por perfusión para recelularización de células de islote.
ECSP14013215A (es) Compuestos novedosos
IN2014CN04037A (es)
BR112013003160A2 (pt) tratamento de diabetes com células precursoras endócrinas pancráticas
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
EP2700708A3 (en) Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination